Please ensure Javascript is enabled for purposes of website accessibility

2 of the Safest Biotech Stocks You'll Find Today

By Alex Carchidi - May 29, 2021 at 6:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They provide the infrastructure and sell the tools that biomedical researchers need to make breakthroughs.

Safety isn't guaranteed with biotech stocks. Between the risks inherent in pioneering new medicines and technologies and the business risks faced by all companies, there's little refuge for cautious investors in the industry. Still, some biomedical companies are safer than others, thanks to their more conservative business models. Every company needs the right materials and facilities to function, and biotechs are no exception.

Selling these products to companies in the industry is thus much safer than directly participating in the drug or technology development process. Let's take a look at a pair of companies that are making money by sitting upstream of riskier biotechs.

Two scientists stand working at separate laboratory benches.

Image source: Getty Images.

1. Alexandria Real Estate

Alexandria Real Estate Equities (ARE 1.87%) is a real estate investment trust (REIT) that specializes exclusively in leasing out laboratory space to biotechs and academic research institutes. Alexandria's customers are a who's who of heavyweights in biopharma. In 2020, tenants like Pfizer, Moderna, Novavax, AstraZeneca, and Johnson & Johnson worked nonstop at its facilities to develop coronavirus vaccines. Coronavirus therapy makers like Vir Biotechnology, AbbVie, and Merck are also among the company's many tenants. In total, 55% of its annual recurring revenue is derived from publicly traded tenants with large market capitalizations.

Alexandria's business model means that its tenants are taking the risks, not investors. In fact, its income is so stable that in 2020 its credit rating was in the top 10% of all publicly traded REITs. While quarterly revenue growth is on the slow side for the industry, at around 9.1% year over year, it's shockingly consistent thanks in part to an occupancy rate of 94.5% and built-in rent increases over time.

Consistent cash flow is another of Alexandria's strengths. Because its income is highly recurring, management rewards investors by paying a quarterly dividend. Right now, Alexandria's stock has a dividend yield of about 2.4%. Over the last 10 years, the dividend payment has increased by more than 142%. So, while that probably won't get you rich anytime soon, it's still another factor in favor of owning the stock.

2. Abcam

Abcam (ABC -0.08%) (ABCM 2.35%) makes the laboratory antibody products that biomedical researchers and drug developers need to do their jobs. While you've probably never heard of the company before, rest assured that everyone in biotech has. According to management, "more than 50% of all life-sciences publications cited using an Abcam product," more than any other company. And more than 98% of customers report that they are satisfied with the company's products. In other words, as long as people are tinkering in life-sciences laboratories, they'll gladly seek Abcam's help.

From 2014 to 2020, its global revenue grew by a compound annual growth rate of 13%, which isn't half bad. In the first half of 2021, total revenue only grew by 6.7% year over year, due in part to the pandemic's negative impact on research activity not related to the novel coronavirus.

Moving forward, the company hopes to expand its penetration of the Chinese life-sciences market. But what makes it a safer stock than any other biomedical reagent company? In short, Abcam's customer mix is split between private companies and academic institutions and research labs. So, if there's some sort of biotech recession, it can still depend on its other customers to survive.

Abcam is also a safe bet because it seems to be taking revenue from its competition over time. Since 2010, Abcam's number of citations in research papers has increased by 13%, while its next five competitors have seen their citation volume shrink by 15%. Researchers need to cite the products that they use, so this is a favorable sign. Plus, it points to the most important thing about this stock: Selling research tools is nowhere near as risky as doing research firsthand.

In sum, Abcam -- like Alexandra Real Estate Equities -- is a great option for investors seeking exposure to the growth of the biotech sector, but who don't want to take on the steep risks of buying stock in a drug developer.

Alex Carchidi owns shares of AbbVie. The Motley Fool recommends Abcam, Alexandria Real Estate Equities, Johnson & Johnson, and Moderna. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abcam Plc Stock Quote
Abcam Plc
$15.69 (2.35%) $0.36
Alexandria Real Estate Equities, Inc. Stock Quote
Alexandria Real Estate Equities, Inc.
$170.09 (1.87%) $3.12
Abcam Plc Stock Quote
Abcam Plc
$1,252.00 (-0.08%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.